,i #aaf? ,,congress #b;d ,session ,h4 ,r4 #gjeg ,,9 ,,! ,,h\se ,,( ,,repres5tatives ,may #bh1 #bjbj,mr4 ,rask9 introduc$ ! foll[+ bill2 :i* 0 ref]r$ to ! ,committee on ,en]gy & ,comm]ce ,a ,,bill ,to am5d ! ,public ,heal? ,s]vice ,act to au?orize & provide = ! expansion1 int5sification1 & coord9ation ( ! programs & activities ( ! ,national ,in/itutes ( ,heal? ) respect to po/-viral *ronic neuroimmune diseases1 specifically myalgic encephalomyelitis_/*ronic fatigue syndrome 7,,me_/,,cfs71 to support ! ,,covid-#ai response1 & = o!r purposes4 #a4 ,%ort title ,?is ,act may be cit$ z ! ,und]/&+ ,,covid-#ai ,subsets & ,,me_/,,cfs ,act or ! ,u4,c4,s4 ,,me_/,,cfs ,act4 #b4 ,f9d+s ,congress f9ds ! foll[+3 7#a7 ,z ( ,may #bg1 #bjbj1 ! virus t causes ,,covid-#ai has infect$ #a4g million ,am]icans1 _m ( :om may nev] recov]1 & has caus$ ov] #ajj1jjj dea?s4 7#b7 ,myalgic encephalomyelitis_/*ronic fatigue syndrome 7,,me_/,,cfs7 is a s]i\s1 *ronic1 & multisy/emic disease associat$ ) survivors ( viral infections4 7#c7 ,subsets ( ,,covid-#ai pati5ts are pres5t+ ) ,,me_/,,cfs symptoms1 su* z bra9 inflammation1 & exp]ts expect a significant increase ( ,,me_/,,cfs cases 9 ! next two ye>s 9 ! ,unit$ ,/ates foll[+ ! ,,covid-#ai epidemic4 7#d7 ,,me_/,,cfs is *>act]iz$ by *ronic or lifelong symptoms across multiple body sy/ems includ+ po/-ex]tional malaise 7,,pem71 bra9 inflammation1 fev]1 pa91 neurological1 immune & cognitive dysfunction1 & swoll5 gl&s or t5d] lymph nodes :i* are mo/ likely to appe> foll[+ a viral infection1 l coronaviruses1 ,ep/e9-,b>r1 or ,q-,riv] fev]4 7#e7 ,! sev]ity ( bo? ,,covid-#ai & ,,me_/,,cfs ranges f mild to completely debilitat+ & 9 "s cases c be le?al4 7#f7 ,! cause ( ,,me_/,,cfs is unkn[n4 ,!re is no diagno/ic te/ = ,,me_/,,cfs1 & !re is no treatm5t = ,,me_/,,cfs t is approv$ by ! ,food & ,drug ,adm9i/ration4 7#g7 ,physicians are n suffici5tly educat$ on ! prop] diagnosis ( ,,covid-#ai subsets1 ,,me_/,,cfs1 or curr5t treatm5ts = ,,me_/,,cfs4 ,?is leads to excess heal? c>e co/s1 errors 9 treatm5ts1 & h>m to pati5ts4 7#h7 ,pati5ts ) ,,me_/,,cfs frequ5tly suff] = ye>s be=e receiv+ an accurate diagnosis & are (t5 giv5 h>mful treatm5t recomm5dations expos+ !m to unnecess>y & co/ly te/s & proc$ures1 z well z ne$less suff]+ & exp5se4 7#i7 ,! economic impact ( ,,me_/,,cfs is high4 ,! annual co/ 9 ! ,unit$ ,/ates = ,,me_/,,cfs is e/imat$ to be betwe5 #ag1jjj1jjj1jjj & #bd1jjj1jjj1jjj 9 m$ical exp5ditures & lo/ productivity4 ,! ov]:elm+ majority ( p ) ,,me_/,,cfs are unable to "w4 7#aj7 ,,me_/,,cfs symptoms are consi/5t ) o!r neuroimmune diseases1 su* z ,gulf ,w> ,illness1 & are recogniz$ z a s]i\s & disabl+ issue = milit>y vet]ans1 p>ticul>ly ^? :o h be5 deploy$ 9 w> zones & exp]i5ce =eign toxic or viral exposure4 7#aa7 ,,me_/,,cfs affects individuals ( e age1 racial1 e?nic1 & socioeconomic gr\p1 includ+ *ildr54 ,rese>* %[s t ,,me_/,,cfs is two to f\r times m likely to occur 9 wom5 ?an m54 7#ab7 ,! ,national ,in/itute ( ,neurological ,disord]s & ,/roke ( ! ,national ,in/itutes ( ,heal? unanim\sly accept$ ! rec5t report ( ! ,national ,advisory ,neurological ,disord]s & ,/roke 7,,n&s7 ,c\ncil ,work+ ,gr\p = ,,me_/,,cfs :i* id5tifies rese>* gaps & opportunities ready = inve/m5t4 #c4 ,rese>* on ,,covid-#ai subsets & po/-viral *ronic neuroimmune diseases ,subp>t #g ( "p ,c ( title ,,iv ( ! ,public ,heal? ,s]vice ,act 7#db ,u4,s4,c4 #bhe;g et seq47 is am5d$ by add+ at ! end ! foll[+3 #deb;,h4 ,rese>* on ,,covid-#ai subsets & po/-viral *ronic neuroimmune diseases 7a7 ,9 g5]al ,! ,director ( ,,nih1 9 coord9ation ) or act+ ?r\gh ! ,director ( ! ,in/itute1 %all conduct & support rese>* & relat$ activities conc]n+ ! diagnosis1 treatm5t1 & risk factors ( po/-viral *ronic neuroimmune diseases1 specifically myalgic encephalomyelitis_/*ronic fatigue syndrome 79 ?is section ref]r$ to z ,,me_/,,cfs71 ,,covid-#ai pati5ts exhibit+ ,,me_/,,cfs symptoms1 & survivors ( ,,covid-#ai ) ,,me_/,,cfs4 ,su* rese>* %all attempt to bett] und]/& ! und]ly+ cause or causes ( ,,me_/,,cfs to r$uce ! rate ( onset ( ,,me_/,,cfs 9 ,,covid-#ai survivors or id5tify effective treatm5ts & improve outcomes = ,,covid-#ai survivors ) ,,me_/,,cfs4 7b7 ,data collection ,9 c>ry+ out subsection 7a71 ! ,director ( ,,nih %all implem5t a sy/em to collect data on ,,me_/,,cfs1 :i* c be contribut$ to & utiliz$ by rese>* p>tn]s1 & :i* provides = ! collection ( su* data includ+-- 7#a7 epidemiologic in=mation ) respect to ! incid5ce1 preval5ce1 & impact ( ,,me_/,,cfs 9 ! ,unit$ ,/ates1 ,,covid-#ai pati5ts exhibit+ ,,me_/,,cfs symptoms1 & survivors ( ,,covid-#ai ) ,,me_/,,cfs2 7#b7 prim>y data on ,,me_/,,cfs natural hi/ory & symptom progress1 includ+ relat$ data on ! po/-viral nature1 risk factors1 & v>i\s conditions kn[n to be comorbid ) ,,me_/,,cfs2 7#c7 ! availability ( m$ical & social s]vices = individuals ) ,,me_/,,cfs & _! families2 & 7#d7 ! disaggregation ( su* data by population & geographical region4 7c7 ,collaborative rese>* c5t]s ,9 c>ry+ out subsection 7a71 ! ,director ( ,,nih %all aw>d grants & contracts to public or nonpr(it private entities to pay all or "p ( ! co/ ( e/abli%+ or exp&+ collaborative rese>* c5t]s = ,,me_/,,cfs1 includ+ ! co/s ( /akehold] engagem5t & pati5t outrea* programs4 7d7 ,develop+ rese>* ag5da ,! ,director ( ,,nih1 9 coord9ation ) ! ,director ( ! ,in/itute1 ! ,trans-,,nih ,,me_/,,cfs ,work+ ,gr\p1 int]ag5cy p>tn]s1 /akehold]s1 & disease exp]ts1 %all develop a rese>* ag5da-- 7#a7 draw+ f ! ,septemb] #bjai report ( ! ,national ,advisory ,neurological ,disord]s & ,/roke ,c\ncil ,work+ ,gr\p = ,,me_/,,cfs2 & 7#b7 prioritiz+ outcomes = ,,covid-#ai pati5ts exhibit+ ,,me_/,,cfs symptoms & survivors ( ,,covid-#ai ) ,,me_/,,cfs4 7e7 ,rese>* program ,9 c>ry+ out subsection 7b71 ! ,director ( ,,nih1 9 coord9ation ) ! ,director ( ! ,in/itute & ! directors ( o!r national rese>* in/itutes & c5t]s1 & utiliz+ ! ,national ,in/itutes ( ,heal?'s process ( sci5tific pe] review1 %all-- 7#a7 prioritize opportunities t accel]ate diagnosis & id5tify effective treatm5ts = ,,covid-#ai pati5ts exhibit+ ,,me_/,,cfs symptoms & survivors ( ,,covid-#ai ) ,,me_/,,cfs2 7#b7 prioritize projects ) new & e>ly c>e] rese>*]s2 7#c7 exp& ,,me_/,,cfs rese>* programs includ+ ! cont9uation ( exi/+ /udies1 remote conv5+s ) /akehold]s1 & new ,,me_/,,cfs disease specific fund+ ann\ncem5ts1 includ+ set-aside funds2 & 7#d7 explore opportunities to p>tn] ) ! ,dep>tm5t ( ,def5se & ! ,dep>tm5t ( ,vet]ans ,affairs to increase rese>* & improve pati5t c>e reg>d+ ,,me_/,,cfs t commonly impact vet]ans & active duty milit>y p]sonnel4 7f7 ,report to ,congress ,n lat] ?an #bd mon?s aft] ! date ( enactm5t ( ! ,und]/&+ ,,covid-#ai ,subsets & ,,me_/,,cfs ,act1 ! ,director ( ,,nih %all submit a report to ,congress on ! progress made 9 ga!r+ data & exp&+ rese>* on ! onset & cl9ical c>e ( ,,covid-#ai survivors ) ,,me_/,,cfs1 includ+ ! rate at :i* ,,covid-#ai survivors are diagnos$ ) ,,me_/,,cfs4 ,su* report %all summ>ize ! grants & rese>* fund$1 by ye>1 "u ?is section4 7g7 ,au?orization ( appropriations ,!re is au?oriz$ to be appropriat$ to c>ry out ?is section #ae1jjj1jjj = ea* ( fiscal ye>s #bjbj ?r\gh #bjbd4 4 #d4 ,promot+ public aw>5ess ( po/-viral *ronic neuroimmune diseases ,"p ,b ( title ,,iii ( ! ,public ,heal? ,s]vice ,act 7#db ,u4,s4,c4 #bdc et seq47 is am5d$ by add+ at ! end ! foll[+3 #cbj;,b4 ,public aw>5ess ( po/-viral *ronic neuroimmune diseases 7a7 ,9 g5]al ,! ,secret>y may engage 9 public aw>5ess & education activities to increase und]/&+ & recognition ( po/-viral *ronic neuroimmune diseases1 specifically myalgic encephalomyelitis_/*ronic fatigue syndrome 79 ?is section ref]r$ to z ,,me_/,,cfs74 7b7 ,activities includ$ ,activities "u subsection 7a7 may include ! di/ribution ( pr9t1 film1 & web-bas$ mat]ials t>get+ heal? c>e provid]s & ! public & prep>$ & dissem9at$ 9 conjunction ) pati5t organizations t conduct rese>* on or treat ,,me_/,,cfs4 7c7 ,emphasis ,! in=mation express$ ?r\gh activities "u subsection 7a7 %all emphasize-- 7#a7 basic in=mation on ,,me_/,,cfs1 ! symptoms1 preval5ce1 & frequ5tly co-occurr+ conditions2 & 7#b7 ! importance ( e>ly diagnosis1 & prompt & accurate treatm5t ( ,,me_/,,cfs1 includ+ mo/ rec5t treatm5t recomm5dations4 4